Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 142   

Articles published

GSK 1,559.26 -1.24 (-0.08%)
price chart
Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc ...
Point of care business EKF Diagnostics (LSE: EKF) has risen by over 5% today. This sharp hike in its share price is due to a positive update which shows that it has beaten expectations for the 2016 financial year.
NeRRe, A GlaxoSmithKline Plc (NYSE:GSK) Spinout Raises �23 Million For NK ...
NeRRe Therapeutics, which is a GlaxoSmithKline Plc (NYSE:GSK) spinout, has raised �23 million ($28 million) in a Series B financing round.
What do Analysts suggest for: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
GlaxoSmithKline PLC (GSK) Shares Sold by Stephens Inc. AR  Sports Perspectives
Oral Vaccines Market 2017 GlaxoSmithKline Plc, Hualan Biological Engineering ...
13-Oral-Vaccines Top Manufacturers Analysis of Oral Vaccines GlaxoSmithKline Plc, Hualan Biological Engineering , Janssen Pharmaceuticals, MedImmune (US), Merck & Co.
Most Recent analysts Ratings: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
Analyst Activity – Goldman Sachs Group Inc. Reiterates Buy on ...  Market Exclusive
GlaxoSmithKline PLC (GSK) Shares Bought by Commonwealth Equity Services Inc  Sports Perspectives
GlaxoSmithKline plc's (GSK) "Buy" Rating Reaffirmed at Bryan, Garnier & Co
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its “buy” rating reaffirmed by stock analysts at Bryan, Garnier & Co in a research report issued on Monday.
GlaxoSmithKline plc (GSK) PT Lowered to GBX 1600  The Cerbat Gem
GlaxoSmithKline plc's (GSK) Underperform Rating Reiterated at BNP Paribas  BBNS
Steady As She Goes, Accelerated Growth Puts Stock in Focus: GlaxoSmithKline ...
Shares of GlaxoSmithKline plc (NYSE:GSK) have been experiencing an accelerated earnings and sales growth over the past 5 years.
What are Analysts opinions on: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
BNP Paribas Reaffirms "Underperform" Rating for GlaxoSmithKline ...  Sports Perspectives
GSK global pharma president Abbas Hussain to leave
LONDON--GlaxoSmithKline PLC's pharmaceuticals chief Abbas Hussain is to leave the company after missing out on the top job, and will be replaced by AstraZeneca PLC executive Luke Miels.
TOP NEWS: GlaxoSmithKline Poaches AstraZeneca's Miels To Lead Pharma  London South East (registration) (blog)
Corporate executive team changes  Satellite PR News (press release)
Is this under-the-radar pharma stock the next GlaxoSmithKline plc?
Beximco Pharmaceuticals (LSE: BXP) flies under the radar of most investors despite the company's enormous potential. Operating out of Bangladesh, Beximco designs, manufactures and supplies generic versions of drugs that have come off patent.